Our Services
With extensive experience of taking programs from inception through to CMC, our chemists focus on delivering the right compounds into the right assay at the right time. Combining RxCelerate’s unique in silico approaches with highly efficient compound synthesis enables rapid hit finding, allowing us to advance from initial ideas to progressable hits faster than traditional methods.
This same approach drives our hit-to-lead and lead optimisation campaigns, ensuring we reach key proof of concept studies as quickly as possible to maximise program value. Our expertise in route development ensures a smooth transition to CMC, with sufficient materials supplied for discovery-phase studies. Underpinning this are our robust in-house compound management and logistics capabilities that seamlessly integrate with our network of specialist partners.
COMPOUND DESIGN
Compound design based on existing SAR, drug-likeness, and molecule functionality, working in partnership with our in-silico division, ProsaRx.
SYNTHESIS MANAGEMENT
Closely managed outsourced synthesis of simpler molecules at our trusted partner CROs, aiding with troubleshooting and quality checking.
COMPLEX SYNTHESIS
Extensive synthetic expertise to carry out route development for complex molecule synthesis in-house, in addition to process development for scale-up.
cmc MANAGEMENT
Management of GMP scale up activities at preferred partner CROs, as well as coordination of pre-clinical tox campaigns.
STORAGE & LOGISTICS
Compound storage, logistics, and database management for both chemical and biological data.
PROJECT MANAGEMENT
Management of all aspects of hit finding, hit to lead and lead optimisation campaigns to ensure rapid progression.
Our Approach
With decades of experience across a wide range of therapeutic areas, our agile and dynamic medicinal chemists are highly skilled in designing active, drug-like molecules. By combining in-house synthetic expertise with trusted outsourced providers, we deliver the optimal mix of chemistry resource for each project, ensuring rapid progress whilst keeping costs low.
Taking a bespoke approach to each program enables us to focus on the most value-adding work, whilst close integration with our in vitro and in vivo biology teams allows us to react instantly to new data. This means we can closely align our incentives with those of our clients, setting us apart from traditional CROs.
RxCelerate offers a unique business model catering to both small molecules and biologics. We work with you to drive your asset through drug discovery, preclinical research and beyond.
Our combination of integrated teams and unique technologies allows RxCelerate to develop the optimal drug discovery strategy to deliver pharma-grade drug candidates quickly and at a fraction of the cost of traditional approaches.